Oruka Therapeutics Reports Highly Positive Phase 2a Data for ORKA-001 in Psoriasis, Supporting Annual Dosing Potential
Summary
Oruka Therapeutics reported strong Phase 2a clinical trial results for ORKA-001 in psoriasis, demonstrating high efficacy, a favorable safety profile, and supporting the potential for annual dosing.
Key Events
-
ORKA-001 Achieves Primary Endpoint
The Phase 2a EVERLAST-A trial met its primary endpoint, with 63.5% of patients treated with ORKA-001 achieving PASI 100 (complete skin clearance) at Week 16, compared to 4.8% for placebo (p < 0.0001).
-
Strong Secondary Efficacy Results
Key secondary endpoints were also met, including PASI 90 in 82.5% of patients and IGA 0 (clear skin) in 63.5% of patients, demonstrating broad and deep efficacy.
-
Favorable Safety Profile
ORKA-001 was generally well tolerated, with a safety profile consistent with the IL-23p19 inhibitor class. No serious treatment-emergent adverse events or discontinuations due to adverse events were reported in the treatment arm.
-
Annual Dosing Potential Supported
Updated Phase 1 pharmacokinetic and pharmacodynamic data continue to support the potential for once-yearly dosing, with sustained drug concentrations and IL-23 pathway inhibition observed through 52 weeks.
Analysis
Oruka Therapeutics announced highly positive Week 16 data from its Phase 2a EVERLAST-A trial for ORKA-001 in moderate-to-severe psoriasis. The drug achieved its primary endpoint of PASI 100 (complete skin clearance) in 63.5% of patients, significantly outperforming placebo. Key secondary endpoints like PASI 90 and IGA 0 were also met with strong results. The favorable safety profile, consistent with its class, combined with updated Phase 1 data supporting potential once-yearly dosing, positions ORKA-001 as a potentially best-in-class treatment in a competitive market. This strong clinical validation significantly de-risks the program and could drive substantial investor interest, especially as the stock is currently trading near its 52-week high.
At the time of this filing, ORKA was trading at $86.73 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.4B. The 52-week trading range was $8.91 to $71.00. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.